Current Landscape of NTRK Inhibition for Pediatric CNS Tumors

Area of Science:

• Pediatric neuro-oncology
• Molecular oncology
• Genomic characterization of pediatric CNS tumors

Background:

• Molecular platforms have transformed the understanding of pediatric central nervous system (CNS) tumors.
• NTRK fusions are identified as key oncogenic drivers across various tumor types, including pediatric CNS tumors.
• NTRK inhibitors represent a novel targeted therapy approach for these specific pediatric malignancies.

Purpose of the Study:

• To review the current landscape of NTRK inhibitors in treating pediatric CNS tumors.
• To discuss the efficacy and tolerability of NTRK inhibitors in relapsed pediatric CNS tumors.
• To explore the future directions, challenges, and opportunities for NTRK inhibitors in upfront settings and resistance management.

Main Methods:

• Review of existing clinical data and research on NTRK inhibitors in pediatric CNS tumors.
• Analysis of treatment outcomes, including response rates and adverse events.
• Discussion of ongoing and future clinical trials investigating NTRK inhibitors.

Main Results:

• Larotrectinib and entrectinib have demonstrated rapid and significant responses in a notable proportion of pediatric CNS tumor patients with NTRK fusions in the relapsed setting.
• These targeted therapies are generally well-tolerated, with spontaneous bone fractures reported in approximately 20% of patients.
• Current data support the progression of NTRK inhibitors into upfront treatment settings, with multiple clinical trials in progress.

Conclusions:

• NTRK inhibitors are effective targeted therapies for pediatric CNS tumors harboring NTRK fusions, particularly in relapsed cases.
• Optimizing patient selection and developing strategies to overcome potential resistance are crucial for maximizing the benefit of these agents.
• The expanding use of NTRK inhibitors in pediatric neuro-oncology necessitates continued research and clinical investigation.